TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06450106: Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Sponsor: SURGE Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$848,232

Rescue Site Savings

+$565,488

Unlock Full NCT06450106 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06450106 Rescue Dossier →